Written answer
Medicinal Products
The Minister referred the request for improved Pluvicto reimbursement offers to the HSE, which has statutory responsibility for pricing and reimbursement decisions.
2184. Deputy Michael Fitzmaurice asked the Minister for Health if she will write to the Chief Executive of the HSE requesting that the Senior Leadership Team seek an improved commercial offer from, and invite counterproposals from, the applicant (details supplied) for reimbursement of pluvicto (lutetium-177 vipivotide tetraxetan) before finalising its decision following the notice of proposal issued on 12 October 2026, having regard to the HSE’s confirmation that it sought an improved commercial offer and invited multiple counterproposals in respect of skyclarys. [77164/26]
Comment on this
The State recognises the importance of timely access to innovative medicines for patients in Ireland.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the Health Service Executive (HSE), through its Senior Leadership Team has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
The Minister for Health has no role in this statutory process.